Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections

Covid19 Clinical Trial

— CovidEP  

Official title:

Assessment of Therapeutic Plasma Exchange to Improve Respiratory Function by Alleviating Cytokine Storm During Severe Covid-19 Infections Randomised Open-label Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04751643
• Other study ID #: 69HCL20_0518
• Secondary ID: 2020-A03039-30
• Status: Recruiting
• Phase: N/A
• Start date: April 19, 2021
• Est. completion date: December 2022

Study information

• Verified date: April 2021
• Source: Hospices Civils de Lyon
• Contact: Olivier HEQUET, MD, PhD
• Phone: 06 31 91 88 87
• Email: olivier.hequet[@]efs.sante.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Severe Covid-19 (Coronavirus Disease 2019) infections generate major but inappropriate production of cytokines and, in some cases, generate anti-IFN (Interferon) auto-antibodies, inducing acute respiratory distress syndrom (ARDS). Therapeutic plasma exchange (TPE) have been reported to be efficient for improving the hyperinflammatory condition state and the respiratory function, which has been described in case reports or small series.

The study aims to remove cytokines during cytokine storm and anti-IFN auto-antibodies (when present) to prevent developpement of an inappropriate immune response and to improve the clinical response to reanimation treatment, in particular the respiratory parameters leading to a rapid improvement of clinical status. To that aim, the study investigates to compare a treatment using TPE plus usual treatments in intensive care unit (experimental arm) versus usual treatments in intensive care unit (routine arm) in a randomised trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 132
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Hospitalized for COVID-19 confirmed by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) or scanner

• Patients with PaO2/FiO2 between 100 and 200 mmHg requiring non invasive ventilation or high flow oxygen

• At least two biological results suggesting a cytokine storm or hyperinflammatory condition state among : C-reactive protéine (CRP)>50mg/L, Procalcitonin (PCT)>1µg/L, Fibrinogen>5g/L, D-dimer >1000ng/mL, Ferritin > 800ng/mL during the last 72 hours.

• Treatment with corticosteroids (at least 2 intakes of dexamethasone 6 mg or equivalent with another form of corticosteroids)

• Patient affiliated to a social security or similar scheme

• Information and written consent from the patient or if not possible from a confident person

Exclusion Criteria:

• Ventilated intubated patients

• Patient with advanced cancer and without curative possibility

• Bacterial or viral (HIV) infection explaining the worsening (the main reason)

• Body Mass Index > 40

• Impossibility to put a central venous catheter according to investigator's judgement

• Severe hemodynamic instability with mean arterial pressure < 65 mmHg (whatever the noradrenaline dosage used)

• Immunoglobulin A (IgA) deficiency with anti-IgA antibodies

• Inclusion in another study that could interact with the Covidep study (investigator's judgement)

• Patient under legal protection measure

• Pregnant or breastfeeding women

• In case of allergy to amotosalen (psoralens) or AI-FFP (Amotosalen Inactivated Fresh Frozen Plasma) , use Se-FFP (Secured Fresh Frozen Plasma)

Related Conditions & MeSH terms

• ARDS, Human
• Covid19
• Intensive Care Units
• Respiratory Distress Syndrome, Adult

Intervention

Other:
• Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)
Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments. Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation
• Usual treatments in intensive care unit according to the current state of knowledge
Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)

Locations

Country	Name	City	State
France	Centre Hospitalier William Morey	Chalon-sur-Saône
France	Clinique de la Sauvegarde	Lyon
France	Hôpital Croix Rousse	Lyon
France	Hôpital Edouard Herriot	Lyon
France	Hôpital Edouard Herriot	Lyon
France	Groupement Hospitalier Porte de Valence - Montélimar	Montelimar
France	Hôpital Pitié Salpétrière - Assistante Publique des Hôpitaux de Paris	Paris
France	Centre Hospitalier Lyon Sud	Pierre-Bénite
France	Medipole Villeurbanne	Villeurbanne

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Use of intubation and invasive ventilation (IV) between Day 0 (Inclusion Visit) and Day 10	Proportion of patients requiring intubation between Day 0 and Day 10. Intubation use will be measured in both arms at Day 10.	At day 10
Secondary	Assess the adverse events according to CTCAE v5.0	Adverse events according to CTCAE v5.0 measured throughout the study, in both groups, including tolerance to TPEs in the experimental group over the course of the study sessions.	Throughout the study : Day 1 to Day 10 and to the end of the study (Day 60 +/- 2 days)
Secondary	PaO2/FIO2 (Partial Pressure of Oxygen/Fraction of Inspired Oxygen) (mmHg) at day 4 after inclusion (PaO2/FiO2 is a usual parameter for assessing evolution of ARDS)	PaO2/FIO2 (mmHg) at day 4 after inclusion. This parameter will be compared between day 4 and day 0.The change corresponds to an increase of PaO2/FIO2 ratio equal or superior than 20%. The proportion of patients with a PaO2/FiO2 change at Day 4 will be compared between both arms.	At Day 4
Secondary	Percentage of patients weaned from non invasive ventilation	Percentage of patients weaned from high flow oxygen. This parameter is compared between both arms (experimental and control arms).	At day 10
Secondary	Survival at day 10	Percentage of patients alive at day 10 after inclusion. This parameter is compared between both arms.	At day 10
Secondary	Survival at 2 months	Percentage of patients alive at 2 months after inclusion. This parameter is compared between both arms.	At day 60 (+/- 2 days)
Secondary	Percentage of patients without any increase in inflammatory parameters (analysis of C-reactive protein, Fibrinogen,D-Dimers, procalcitonin, Ferritin)	Percentage of patients without any increase in inflammatory parameters (analysis of C-reactive protein, Fibrinogen,D-Dimers, procalcitonin, Ferritin ) at day 4 compared to values at day 0. This parameter is compared between both arms.	At day 4
Secondary	Variation in cytokine and chemokine levels in the cytokine storm	Percentage of patients without any increase in cytokine or chemokine levels. Leucocyte and platelet cytokine or chemokine levels in ng/ml are assessed in both arms. Analysis of the entire panel of cytokines or chemokines defines an improvement or not. Comparison between both arms.	At day 4
Secondary	Percentage of patients with improved phenotype (decreased phenotype of exhausted cells) and improved function (improved proliferation)	Lymphocyte and NK (Natural Killer) labeling and analysis by flow cytometry at day 0 and day 7. Analysis of lymphocyte proliferation (after stimulation) at day 0 and day 7. Analysis of percentage of patients with improved phenotype (decreased phenotype of exhausted cells) and improved function (improved proliferation) ; this parameter is compared between both arms.	At day 7
Secondary	Percentage of patients with decreased platelet activation	Phenotype of platelets and flow cytometry analysis performed before and after TPE or usual treatment. Percentage of patients with decreased platelet activation at day 4 ; this parameter is compared between both arms.	At Day 4
Secondary	Percentage of patients with decreased platelet activation	Phenotype of platelets and flow cytometry analysis performed before and after TPE or usual treatment. Percentage of patients with decreased platelet activation at day 7 ; this parameter is compared between both arms.	At Day 7
Secondary	Change in anti-IFN auto-antibodies type I (a and ?) level	Change in anti-IFN auto-antibodies type I (a and ?) level at day 0 and day 4.	Day 0 and Day 4